Skip to main content
Annex II Entry 1564 CMR30/07/2020

Gallium arsenide

Gallium arsenide is listed in Annex II as a prohibited substance for cosmetic products placed on the EU market.

Prohibited substance— Annex II, EU Regulation 1223/2009
Entry: 1564
CMR

Chemical identity and properties

PubChem 2D chemical structure for CAS 1303-00-0
CAS 1303-00-0PubChem CID 14770

Gallium arsenide

Gallium Arsenide can cause cancer according to California Labor Code. California Office of Environmental Health Hazard Assessment (OEHHA)

IUPAC name
gallanylidynearsane
Molecular formula
AsGa
Molecular weight
144.645 g/mol
Exact mass
143.84717 Da
Topological polar surface area
0.0 Ų
Hydrogen-bond donors
0
Hydrogen-bond acceptors
0
Covalent units
1
Defined stereocentres
0

Also known as

Gallium arsenide (GaAs)Gallium monoarsenideGallium monoarsenide (GaAs)GaAs27FC46GA44Gallium ArsenatumRefChem:58150215-114-8
15 more reported names
CCRIS 4020HSDB 4376EINECS 215-114-8arsinogallaneUNII-27FC46GA44GalliummonoarsenideGallium Arsenide, piecesEC 215-114-8GALLIUM ARSENIDE [MI]Gallium arsenide, pieces, 99.999% trace metals basisGallium arsenide Optical Window, 12.7mm (0.5in) dia x 1mm (0.04in) thickGallium arsenide Optical Window, 12.7mm (0.5in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 25.4mm (1.0in) dia x 2mm (0.08in) thickGallium arsenide Optical Window, 50.8mm (2.0in) dia x 2mm (0.08in) thickGallium arsenide, (single crystal substrate), <100>, diam. x thickness 2 in. x 0.5 mm

Evidence from additional scientific databases

NIH PubChem PUG-View
Exact identifier match14770

Attributed physical-property, hazard, environmental and use annotations.

  • Substance: Gallium Arsenide Source: NTP Technical Reports
  • NTP Technical Report: TR-492: Toxicology and Carcinogenesis Studies of Gallium Arsenide (CASRN 1303-00-0) in F344/N Rats and B6C3F1 Mice (Inhalation Studies) (2000 ) Source: NTP Technical Reports
  • Peer Review Date: 05/21/99 Source: NTP Technical Reports
  • Conclusion for Male Rat: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Rat: Clear Evidence Source: NTP Technical Reports
  • Conclusion for Male Mice: No Evidence Source: NTP Technical Reports
  • Conclusion for Female Mice: No Evidence Source: NTP Technical Reports
  • Summary: Under the conditions of these 2-year inhalation studies, there was no evidence of carcinogenic activity of gallium arsenide in male F344/N rats exposed to 0.01, 0.1, or 1.0 mg/m3. There was clear evidence of carcinogenic activity in female F344/N rats based on increased incidences of benign and malignant neoplasms in the lung. Increased incidences of benign neoplasms of the adrenal medulla and increased incidences of mononuclear cell leukemia were also considered to be exposure related. There was no evidence of carcinogenic activity in male or female B6C3F1 mice exposed to 0.1, 0.5, or 1.0 mg/m3.; Exposure to gallium arsenide caused a spectrum of nonneoplastic lesions in the lung of rats and mice, the larynx of male rats and hyperplasia of the tracheobronchial lymph node in mice. Source: NTP Technical Reports
  • Carcinogen Classification: 1, carcinogenic to humans. (L135) Source: Toxin and Toxin Target Database (T3DB)
  • First Aid: EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.; SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. If symptoms such as redness or irritation develop, IMMEDIATELY call a physician and be prepared to transport the victim to a hospital for treatment.; INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Ap Source: CAMEO Chemicals
  • Signal: Danger Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360F: May damage fertility [Danger Reproductive toxicity]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: Regulation (EC) No 1272/2008 of the European Parliament and of the Council
  • Note: This chemical does not meet GHS hazard criteria for 6.2% (7 of 112) of reports. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H350 (88.4%): May cause cancer [Danger Carcinogenicity]; H360 (50.9%): May damage fertility or the unborn child [Danger Reproductive toxicity]; H372 (88.4%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 112 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 7 of 112 reports by companies.; There are 6 notifications provided by 105 of 112 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
  • Signal: Danger Source: NITE-CMC
  • GHS Hazard Statements: H350: May cause cancer [Danger Carcinogenicity]; H360: May damage fertility or the unborn child [Danger Reproductive toxicity]; H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure]; H372: Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Source: NITE-CMC
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P308+P316, P318, P319, P321, P405, and P501 (click each P-code to see the statement) Source: NITE-CMC
  • Signal: Danger Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
  • Health Effects: Arsenic poisoning can lead to death from multi-system organ failure, probably from necrotic cell death, not apoptosis. Arsenic is also a known carcinogen, esepcially in skin, liver, bladder and lung cancers. (T1, L20) Source: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: Arsenic and its metabolites disrupt ATP production through several mechanisms. At the level of the citric acid cycle, arsenic inhibits pyruvate dehydrogenase and by competing with phosphate it uncouples oxidative phosphorylation, thus inhibiting energy-linked reduction of NAD+, mitochondrial respiration, and ATP synthesis. Hydrogen peroxide production is also increased, which might form reactive oxygen species and oxidative stress. Arsenic's carginogenicity is influenced by the arsenical binding of tubulin, which results in aneuploidy, polyploidy and mitotic arrests. The binding of other arsenic protein targets may also cause altered DNA repair enzyme activity, altered DNA methylation patterns and cell proliferation. (T1, A17) Source: Toxin and Toxin Target Database (T3DB)

Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record

Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.

Additional source coverage and match status
SourceResultChecked
NIH PubChem PUG-ViewExact match2026-08-31

A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.

Retrieved from NIH PubChem on 2026-09-02 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.

Record details

Chemical name

Gallium arsenide

Chemical / IUPAC name

Gallium arsenide

Regulatory information

Regulation

(EU) 2019/831

See every entry this act set

CMR

CategoryCarcinogenicMutagenicReprotoxic
Cat. 1B

Key data

Annex
Entry number
1564

Direct matches are limited for this record, so nearby entries from Annex II are shown as well.

Annex II 1565
Nearby record in the same annex

Vinyl acetate

CAS: 108-05-4
EC: 203-545-4

What Annex II means for Gallium arsenide

Gallium arsenide is listed as a prohibited substance under Annex II of EU Cosmetics Regulation 1223/2009 and must not be intentionally added. Article 17 separately addresses unintended small quantities that are technically unavoidable under good manufacturing practice and compatible with the Article 3 safety requirement.

Formulators must screen their ingredients and raw materials to ensure none contain this substance. Suppliers should provide documentation confirming absence when requested.

The page also surfaces 12 related annex records with overlapping identifiers, annex logic or naming patterns.

Compliance checklist

  • Verify this substance is absent from all raw materials and finished formulations.
  • Request absence confirmation or CoA from raw material suppliers.
  • Document the screening result in the Product Information File (PIF).
  • This substance has CMR classification. Review the CMR table above and verify current Annex II/III status before use.

Frequently asked questions

Yes. Gallium arsenide is listed in Annex II of EU Cosmetics Regulation 1223/2009 and is prohibited as an intentionally added cosmetic ingredient. Article 17 provides a narrow exception for unintended small quantities that are technically unavoidable under good manufacturing practice, provided the product remains safe under Article 3.

CAS 1303-00-0 is the unique numerical identifier assigned to Gallium arsenide by the Chemical Abstracts Service. In cosmetic compliance work, the CAS number is used to cross-reference the substance across regulatory databases, raw material specifications and safety assessment reports. Multiple EU annex entries may share the same CAS number if the same substance appears under different conditions or in different annexes.

Gallium arsenide has a CMR (carcinogenic, mutagenic or reprotoxic) classification under EU CLP Regulation. Under Article 15 of EU Cosmetics Regulation 1223/2009, CMR substances of category 1A or 1B are prohibited in cosmetics unless specifically permitted. Category 2 CMR substances may be used only if assessed safe by the SCCS. Always verify current annex status and any applicable derogations before use.

Use the INCI Checker tool on this site to paste your full ingredient list (INCI) and scan it against all Annex II–VI entries. The tool highlights any ingredients that match restricted, prohibited or allergen-flagged records. This is useful for rapid compliance screening of finished product formulas or raw material declarations.

Source note for Annex II record Gallium arsenide

This page summarizes one Annex II record for Gallium arsenide from public European Commission cosmetic materials and adds linked inventory or identifier matches when available.

Use this record page to review Annex II conditions for Gallium arsenide, but confirm any final regulatory decision against the current official annex wording and source files.

Tools & next steps

Check your formula

Paste a full INCI list to detect Gallium arsenide and other flagged EU annex records in one pass.

INCI Checker

Compare entries

Compare Gallium arsenide side by side with another annex record to review differences in restrictions, concentrations and annex placement.

Compare

Browse the annex

See all records in Annex II and compare regulatory conditions across substances in this annex.

Open Annex II